<DOC>
	<DOCNO>NCT00149942</DOCNO>
	<brief_summary>This open , single arm , explorative study aim investigate evolution gastrointestinal adverse event switch MMF EC-MPS organ transplant patient suffer gastrointestinal adverse event MMF therapy .</brief_summary>
	<brief_title>Conversion Trial From Mycophenolate Mofetil ( MMF ) Enteric-coated Mycophenolate Sodium ( EC-MPS ) Stable Transplanted Patients Suffering From Gastrointestinal ( GI ) Adverse Events While Mycophenolate Mofetil Therapy ( MMF ) Therapy</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Kidney liver transplant patient Currently MMF therapy currently suffer upper low gastrointestinal adverse event Recent graft rejection study Other preexist condition may cause gastrointestinal complaint Use drug know cause gastrointestinal complaint Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Enteric coat mycophenolate sodium</keyword>
	<keyword>transplantation</keyword>
	<keyword>gastrointestinal adverse event</keyword>
	<keyword>Kidney liver transplantation patient experience GI AEs current MMF treatment</keyword>
</DOC>